Biodyne Co. Ltd.
Biodyne Co., Ltd. engages in the development, manufacture, and sale of liquid-based cytology (LBC) equipment and reagent kits for cancer diagnosis in South Korea. The company offers PATHPLORER solution, which preserves and fixes the collected cells; PATHPLORER LBC system, an equipment for processing liquid cytology samples for cancer diagnosis. It exports its products to Japan, Russia, Portugal, … Read more
Biodyne Co. Ltd. (314930) - Total Liabilities
Latest total liabilities as of September 2025: ₩774.37 Million KRW
Based on the latest financial reports, Biodyne Co. Ltd. (314930) has total liabilities worth ₩774.37 Million KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biodyne Co. Ltd. - Total Liabilities Trend (2018–2024)
This chart illustrates how Biodyne Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biodyne Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Biodyne Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SmarTone Telecommunications Holdings Limited
PINK:STTFF
|
USA | $5.69 Billion |
|
Vuzix Corp Cmn Stk
NASDAQ:VUZI
|
USA | $4.59 Million |
|
Chien Kuo Construction Co Ltd
TW:5515
|
Taiwan | NT$4.16 Billion |
|
Namchow Food Group (Shanghai) Co. Ltd.
SHG:605339
|
China | CN¥820.25 Million |
|
Voxel S.A.
WAR:VOX
|
Poland | zł286.16 Million |
|
Ganesha Ecosphere Limited
NSE:GANECOS
|
India | ₹7.72 Billion |
|
Tracsis plc
PINK:TCIIF
|
USA | $32.96 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Biodyne Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 27.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biodyne Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biodyne Co. Ltd. (2018–2024)
The table below shows the annual total liabilities of Biodyne Co. Ltd. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩1.15 Billion | +90.04% |
| 2023-12-31 | ₩603.91 Million | -51.90% |
| 2022-12-31 | ₩1.26 Billion | -82.86% |
| 2021-12-31 | ₩7.32 Billion | -59.85% |
| 2020-12-31 | ₩18.24 Billion | +9.40% |
| 2019-12-31 | ₩16.68 Billion | +33.48% |
| 2018-12-31 | ₩12.49 Billion | -- |